A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 40 do 75 lat
- •Wskaźnik masy ciała (BMI) między 18 a 34 kg/m²
- •Jeśli bierzesz leki na depresję lub lęk (SSRI), musisz być na stałej dawce przez co najmniej 60 dni
- •Potwierdzona diagnoza choroby Parkinsona
- •Brak cech otępienia wykazany badaniem kognitywnym
- •Negatywne wyniki badań na HIV, zapalenie wątroby typu B i C
- •Zdolność do wykonywania wszystkich badań i uczestniczenia w wizytach
- •Gotowość do udzielenia świadomej zgody na udział
✗ Disqualifies
- •Historia alergii lub wrażliwości na lek MTX325
- •Historia poważnych zaburzeń żołądkowych lub jelit, które mogłyby wpłynąć na wchłanianie leku
- •Pozytywny wynik testu na narkotyki
- •Poważne problemy z sercem lub zaburzenia rytmu serca
- •Istotne nieprawidłowości w parametrach medycznych (ciśnienie, puls, temperatura)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (18)
The Royal Adelaide Hospital
Adelaide, Australia
Doherty Clinical Trials
Melbourne, Australia
Monash Health, Kingston Centre
Melbourne, Australia
Centre Hospitalier Universitaire de Lille, Institut Cœur Poumon
Lille, France
Hôpital Henri-Mondor (Créteil, AP-HP), Paris
Paris, France
Pitie-Salpetriere Hospital, Paris
Paris, France
Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse
Toulouse, France
Technische Universitaet Dresden, Dresden
Dresden, Germany
Cambridge Biomedical Research Centre, Cambridge
Cambridge, United Kingdom
Neuroclnx, Glasgow
Glasgow, United Kingdom
Royal Liverpool University Hospital
Liverpool, United Kingdom
Parexel
London, United Kingdom
Perceptive
London, United Kingdom
Simbec-Orion
Merthyr Tydfil, United Kingdom
Freeman Hospital, Newcastle Upon Tyne
Newcastle, United Kingdom
University Hospitals Plymouth NHS Trust, Derriford Hospital
Plymouth, United Kingdom
Salford Hospital (Manchester)
Salford, United Kingdom
Southampton General Hospital, Southampton
Southampton, United Kingdom
Trial contact
Sarah J Fritchley, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.